<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868425</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0538</org_study_id>
    <nct_id>NCT01868425</nct_id>
  </id_info>
  <brief_title>ACL Repair and Multimodal Analgesia</brief_title>
  <official_title>ACL Repair and Multimodal Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of an aggressive multimodal regimen versus
      standard multimodal for ACL repair using hamstring graft for patients having surgery in our
      outpatient surgicenter.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date>April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>opioid consumption in the immediate postoperative period</measure>
    <time_frame>time from post-operative arrival in recovery room to discharge from the outpatient surgery center</time_frame>
    <safety_issue>No</safety_issue>
    <description>this data will be entered into the patients electronic medical record and collected from their chart once the patient has been discharged.  the &quot;immediate postoperative period&quot; covers the patients entire time in the outpatient surgery center after they have entered the recovery room postoperatively.  The amount of time they remain in the outpatient sugery center postoperatively varies from a minimum of 1 hour to a maximum of 10 hours and an average of 4 hours. .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain score</measure>
    <time_frame>up to 24 hours postoperatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>multimodal:acetaminophen, gabapentin, ketamine, bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aggresssive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pills and injectables</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>multimodal:acetaminophen, gabapentin, ketamine, bupivacaine</intervention_name>
    <description>acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane</description>
    <arm_group_label>multimodal:acetaminophen, gabapentin, ketamine, bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pills and injectables</intervention_name>
    <description>receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane plus placebos of intervention arm meds</description>
    <arm_group_label>placebo pills and injectables</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of orthopedic surgeons on the study team scheduled for ACL repair using
             hamstring graft from the same leg will be considered for inclusion in this study.
             Other inclusion criteria are as follows:

               1. American Society of Anesthesiologists (ASA) physical status 1-3

               2. 18-55 years of age, inclusive

               3. BMI of &lt; 40 kg/m2.

               4. Consents to general anesthesia and pre-operative femoral nerve block for case.

                  Exclusion Criteria:

                  Exclusion criteria include:

               1. Any contraindication to a femoral nerve block

               2. Allergy to local anesthetics, nonsteroidal anti-inflammatory medications,
                  ketamine, acetaminophen, hydromorphone, oxycodone

               3. Peripheral or central nervous system disease

               4. Renal or hepatic impairment

               5. History of opioid dependence or current regular narcotic use

               6. Significant psychiatric disease

               7. Pregnancy or lactation (by verbal report)

               8. Seizure Disorder

               9. History of post- operative nausea and vomiting

              10. Latex allergy

              11. Clinically significant cardiac or pulmonary disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>melanie j Donnelly</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>melanie j donnelly, md</last_name>
    <phone>608-263-5034</phone>
    <email>mjdonnelly@wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>melanie j donnelly, md</last_name>
      <phone>608-263-5034</phone>
      <email>mjdonnelly@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>melanie j donnelly, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>May 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
